PARK7 inhibits the activation of MAP3K5 by forming the PARK7/MAP3K5 complex under conditions of mild oxidative stress in order to protect against chemotherapy-induced oxidative stress that leads to apoptosis and autophagy in various cancer cells, including human osteosarcoma, colon cancer, hepatocellular carcinoma, and oral epidermoid carcinoma cells. Here, MAP3K5 is linked to colonic neoplasm.